Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world

Men vs women in emerging markets

Men vs women in emerging markets

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging markets.

While a wide-range range of societal and economic factors influence health outcomes, one of the most significant factors is gender. In addition to overall morbidity and mortality, certain health issues are more commonly associated with one gender. But while biology plays a role, it is predominantly the way in which society structures and shapes men’s and women’s lives that result in health inequalities. Gender norms, roles and expectations vary between cultures, particularly in emerging markets, and affect the way in which health care is accessed. Our latest interactive infographic compares the lives of men vs women in the BRIC emerging markets, and explores how societal factors impact their respective health outcomes.

read more »

South Korea: The next global player?

South Korea: The next global player?

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two conflicting global health indicators: longest life expectancy and highest suicide rates.

Over the past two decades South Korea has experienced rapid economic growth. Low unemployment, rising incomes and increased health insurance coverage have all contributed to the development of a robust healthcare sector and catalysed pharmaceutical sales. South Korea is currently the 13th largest pharmaceutical market in the world and the third largest in Asia, with predicted compound annual growth rate (CAGR) of 2.4%. increasing from US$18.6 billion in 2016 to US$20.4 billion by 2020.

read more »

  • Posted by Julie Denny
  • July 31, 2017
  • Videos

20 questions: Round 4

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What’s been the funniest thing to happen to you whilst you’ve been at Research Partnership?"

read more »

Will gene therapies finally be commercially viable to pharma?

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when attempting to develop this technology. We review gene therapy’s chequered past, look at recent developments in this field and consider the future for gene therapies on their way to market.

Genes are segments of DNA which code instructions for your cells to make proteins. Many inherited disorders are a result of faulty genes which encode incorrect instructions for making specific proteins, either the proteins themselves are defective or the gene may have faulty expression which can result in over-expression so over-production of a certain kind of protein. In the case of cancer, there can be multiple external and internal factors which lead to production of genetically mutated cancerous cells.

read more »

How wargaming was used to understand the likely future HCV landscape and give strategies for brand success

How wargaming was used to understand the likely future HCV landscape and give strategies for brand success

Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of development of both our client’s product and the competitors, a number of different scenarios could have played out. Consequently, the company wanted to conduct research in order to feed into strategy development for their product. What would physicians think of the new entrants and how could this be leveraged to ensure a successful launch?

read more »